

IC13 Rec'd PCT/PTO 27 APR 2005

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)  
(Use several sheets if necessary)

Date Submitted to PTO: April 27, 2005

ATTY DOCKET NO.  
2005\_0727ASERIAL NO.  
NEW

10/532667

APPLICANT  
Yu MOMOSE et al.FILING DATE  
April 27, 2005

GROUP

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
RA	AA	5,464,860	11/1995	Lepage et al.			
	AB	5,250,504	10/1993	Maravetz			
	AC	4,835,280	5/1989	Martens et al.			
	AD	4,172,136	10/1979	Berger et al.			

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	AE	03/049702	6/2003	WO			
	AF	02/098852	12/2002	WO			
	AG	00/75120	12/2000	WO			
	AH	1 148 053	10/2001	EP			
	AI	0 153 850	9/1985	EP			
	AJ	0 630 894	12/1994	EP			
	AK	86/00307	1/1986	WO			
	AL	00/01679	1/2000	WO			Abstract
	AM	01/14372	3/2001	WO			

## OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

ht	AN	T. M. Monteiro et al., "Synthesis and analgesic activity of new pyrazole-4-carboxanilides and (E)-3-pyrazol-4-ylpropananilides", Revista Portuguesa De Farmacia, Vol. 49, No. 4, 1999, pp. 153-160, with English translation.
↑	AO	M. K. Bratenko et al., "Functionally Substituted 3-Heterylpyrazoles: XI. 3-[3-Aryl (heteryl)pyrazol-4-yl]propenoic and Propanoic Acids", Russian Journal of Organic Chemistry, Vol. 38, No. 8, 2002, pp. 1171-1177.
↓	AP	Patent Abstracts of Japan, Vol. 1998, No. 12, October 31, 1998 & JP 10 195063 A, July 28, 1998 *abstract*.
EXAMINER	DATE CONSIDERED 5/25/07	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

JCT3 Rec'd PCT/PTO 27 APR 2005

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)  
(Use several sheets if necessary)

Date Submitted to PTO: April 27, 2005

ATTY DOCKET NO.  
2005\_0727ASERIAL NO.  
NEW 10/532667APPLICANT  
Yu MOMOSE et al.FILING DATE  
April 27, 2005

GROUP

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
RA	BA	3,702,330	11/1972	Hoff et al.			
RA	BB	2004/0204417	10/2004	Perez et al.			Corresponds to AF
	BC						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
RA	BD	4-184435	7/1992	JP			Abstract
↓	BE	2003/099793	12/2003	WO			
↓	BF	03/072554	9/2003	WO			Abstract
	BG						
	BH						

## OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

RA	BI	M. Ohta et al., "Novel 5-Hydroxytryptamine (5-HT <sub>2</sub> ) Receptor Antagonists. I. Synthesis and Structure-Activity Relationships of Conformationally Restricted Fused Imidazole Derivatives" Chem. Phar. Bull. Vol. 44, No. 5, 1996, pp. 991-999.
↓	BJ	Y. Yuen-Lang et al., "Chemotherapeutic Studies on Schistosomiasis XXXIII. Synthesis of β-(5-Nitroimidazol-2-Yl) Acrylamides and Related Compounds", Pharmaceutical Industry, Vol. 17, No. 10, 1986, pp. 444-448, with English translation.
↓	BK	Y. Z. Ling et al., "17-Imidazolyl, Pyrazolyl, and Isoxazolyl Androstene Derivatives. Novel Steroidal Inhibitors of Human Cytochrome C <sub>17,20</sub> -Lyase (P450 <sub>17α</sub> )", J. Med. Chem., Vol. 40, No. 20, September 26, 1997, pp. 3297-3304.
↓	BL	R. Plate et al., "Synthesis and Muscarinic Activities of 3-(Pyrazolyl)-1,2,5,6-tetrahydropyridine Derivatives", Bioorganic & Medicinal Chemistry, Vol. 4, No. 2, February 1996, pp. 227-237.
↓	BM	C. S. Lee et al., "Carbon-Carbon Linked (Pyrazolylphenyl)oxazolidinones with Antibacterial Activity Against Multiple Drug Resistant Gram-Positive and Fastidious Gram-Negative Bacteria", Bioorganic & Medicinal Chemistry, Vol. 9, No. 12, December 2001, pp. 3243-3253.
↓	BN	R. Plate et al., "Synthesis and In Vitro Muscarinic Activities of a Series of 3-(Pyrazol-3-yl)-1-azabicyclo[2.2.2]octanes", Bioorganic & Medicinal Chemistry, Vol. 8, No. 2, February 2000, pp. 449-454.

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

IC13 Rec'd PCT/PTO 27 APR 2005

Sheet 3 of 3		INFORMATION DISCLOSURE STATEMENT	
FORM PTO 1449 (modified)  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary)  Date Submitted to PTO: April 27, 2005		ATTY DOCKET NO. 2005_0727A	SERIAL NO. NEW <b>10/532667</b>
		APPLICANT Yu MOMOSE et al.	
		FILING DATE April 27, 2005	GROUP



  

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS <sup>9</sup>	SUBCLASS	FILING DATE IF APPROPRIATE	
	CA						
	CB						

FOREIGN PATENT DOCUMENTS							
DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO		
CC							
CD							
CE							
CF							
CG							

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)		
	CH	R. W. Harper et al., "Leukotriene B <sub>4</sub> (LTB <sub>4</sub> ) Receptor Antagonists: A Series of (Hydroxyphenyl)pyrazoles", J. Med. Chem., Vol. 37, No. 15, July 22, 1994, pp. 2411-2420.
	CI	G. R. Bebernitz et al., "The Effect of 1,3-Diaryl-[1H]-pyrazole-4-acetamides on Glucose Utilization in ob/ob Mice", J. Med. Chem., Vol. 44, 2001, pp. 2601-2611.
	CJ	
	CK	
	CL	
	CM	

EXAMINER	DATE CONSIDERED
----------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.